Background: Genital warts are a common sexually transmitted disease caused by human
papillomavirus. Imiquimod is a novel immune-response modifier capable of inducing a …

Genital human papillomavirus infection is one of the most common sexually transmitted
diseases. Imiquimod is a new agent, an immune-response modifier, that has been …

Imiquimod is a topically active immunomodulatory agent that is formulated as a 5% cream
for application by the patient. It is the first agent of its class, the immune response modifiers …

Imiquimod, an imidazoquinoline amine, is an immune response modifier recently approved
for the topical treatment of external genital and perianal warts. Although the majority of …

Imiquimod is a novel synthetic molecule with potent immune-modifying activities. Formulated
in a 5% vanishing cream as Aldara™, this self-applied therapy has shown good efficacy and …

The mechanism of action of imiquimod 5% cream applied topically to patients with genital
warts was evaluated in a double-blind, placebo-controlled study. Imiquimod (16 patients) or …

Background Medical therapy for genital warts remains suboptimal. The topical interferon and
cytokine inducer, imiquimod, has been proved effective for the treatment of external genital …

Background and Objective: Imiquimod (Aldara) is an immune response modifier used
primarily to treat anogenital warts. Imiquimod induces cytokines and enhances cell …

Objective To compare the safety and effectiveness of 5% and 1% imiquimod cream with
vehicle cream in the treatment of external anogenital warts. Design Randomized, double …

Imiquimod, an imidazoquinoline amine, is an immune response modifier first FDA-approved
for the treatment of external genital and perianal warts in 1997. Since its appearance on the …